Log in to save to my catalogue

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7101242

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

About this item

Full title

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2020-02, Vol.382 (6), p.545-553

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Using cord blood as an allogeneic lymphocyte source, the investigators in this study infused natural killer cells that had been modified to express an anti-CD19 CAR into 11 patients with CD19-positive lymphoid cancers. Most patients had an antitumor response with very few toxic effects.

Alternative Titles

Full title

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7101242

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7101242

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1910607

How to access this item